ArticleAsian Pacific journal of cancer prevention : APJCP2026
Whole-Genome Analysis of Multidrug-Resistant Escherichia coli from Bloodstream Infections in Iraqi Cancer Patients.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chimeric vaccine based on Iraqi HLA alleles against a predominant localFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Iraq, oncology patients with bloodstream infections face escalating treatment challenges due to rising antimicrobial resistance in Escherichia coli, compounded by limited diagnostic capacity and restricted therapeutic options. However, data from oncology settings in Iraq are limited. This study aimed to characterize and compare the antimicrobial resistance gene profiles of multidrug-resistant and antibiotic-sensitive E. coli isolates from cancer patients, to inform infection control and stewardship strategies.
methodsA prospective, multicenter investigation was conducted in three oncology hospitals in Baghdad. Fifty-five Escherichia coli bloodstream isolates, 36 multidrug-resistant (MDR) (65.5%) and 19 antibiotic-sensitive (34.5%), underwent phenotypic susceptibility testing using VITEK® 2 and disk diffusion. Whole-genome sequencing (Illumina MiSeq) was performed, and antimicrobial resistance genes (ARGs) were identified using AMRFinderPlus and classified by functional category.
resultsMDR isolates showed a broad resistome dominated by efflux systems. Across all isolates, a total of 36 unique antimicrobial resistance genes were identified, underscoring substantial resistome diversity., efflux pump genes were detected in 100%, β-lactamase genes in 88.9%, macrolide resistance genes in 66.7%, tetracycline resistance genes in 55.6%, and aminoglycoside resistance genes in 41.7%. Representative determinants included AcrAB-TolC/EmrAB-TolC/MdtABC-TolC (efflux) and BlaEC family/CMY-42/TEM types (β-lactams). Among sensitive isolates, only 11 antibiotic-associated genes, mainly efflux or regulators (e.g., acrF, emrD, emrR, emrY, tolC; regulators marR, evgA; target parC; others baeS, cpxA, cysB), overlapped with MDR, suggesting a shared core that is insufficient alone for phenotypic resistance without additional high-level mechanisms.
conclusionsMultidrug-resistant E. coli from oncology patients harbor dense, efflux-driven resistomes supplemented by diverse β-lactamases and other resistance determinants, while sensitive isolates retain a limited core set of genes. Genomic surveillance in cancer centers is critical for anticipating resistance emergence and informing targeted antimicrobial strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.